DeFloria Receives Investigational New Drug Application Clearance from FDA for Phase 2 Clinical Trial of AJA001, an Oral Cannabinoid Drug Being Developed for the Treatment of Autism Spectrum Disorder (ASD)
DeFloria, Inc., a collaboration between Ajna BioSciences PBC and Charlotte's Web Holdings, Inc. (TSX: CWEB, OTCQX: CWBHF), announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug (IND) application for AJA001, an orally delivered, multi-cannabinoid botanical drug, concluding that the Company may proceed with its planned Phase 2 clinical trial. DeFloria is developing AJA001 as a treatment for symptoms of autism spectrum disorder (ASD) and